Mojgan Mazaheri1, Farahnak Assadi2, Simin Sadeghi-Bojd3. 1. Department of Pediatrics, Section of Nephrology, Semnan University of Medical Science, Semnan, Iran. 2. Department of Pediatrics, Division of Nephrology, Rush University Medical Center, 445 East North Water Street, Chicago, IL, USA. fassadi@rush.edu. 3. Department of Pediatrics, Division of Nephrology, Zahedan University of Medical Sciences, Zahedan, Iran.
Abstract
PURPOSE:Bartter syndrome is a rare hereditary salt-losing tubulopathy caused by mutations of several genes in the thick ascending limb of Henle's loop, characterized by polyuria, hypokalemic metabolic alkalosis, growth retardation and normal blood pressure. Cyclooxygenase inhibitors, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors are currently used to treat electrolyte derangements, but with poor response. Whether treatment with acetazolamide, a carbonic-anhydrase inhibitor, would result in better clinical outcomes is unknown. METHODS: We randomly assigned children with Bartter syndrome in a 1:1 ratio to either receiveindomethacin, enalapril, and spironolactone or indomethacin, enalapril, and spironolactone plus acetazolamide once daily in the morning for 4 weeks. After 2 days of washout, participants crossed over to receive the alternative intervention for 4 weeks. The present study examines the serum bicarbonate lowering effect of acetazolamide as an adjunctive therapy in children with Batter syndrome. RESULTS: Of the 43 patients screened for eligibility, 22 (51%), between the ages 6 and 42 months, were randomized to intervention. Baseline characteristics were similar between the two groups. Addition of acetazolamide for a period of 4 weeks significantly reduced serum bicarbonate and increased serum potassium levels, parallel with a reduction in serum aldosterone and plasma renin concentration. The 24-h urine volume, sodium, potassium, and chloride decreased significantly. CONCLUSION: Our data define a new physiologic and therapeutic role of acetazolamide for the management of children with Bartter syndrome.
RCT Entities:
PURPOSE:Bartter syndrome is a rare hereditary salt-losing tubulopathy caused by mutations of several genes in the thick ascending limb of Henle's loop, characterized by polyuria, hypokalemic metabolic alkalosis, growth retardation and normal blood pressure. Cyclooxygenase inhibitors, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors are currently used to treat electrolyte derangements, but with poor response. Whether treatment with acetazolamide, a carbonic-anhydrase inhibitor, would result in better clinical outcomes is unknown. METHODS: We randomly assigned children with Bartter syndrome in a 1:1 ratio to either receive indomethacin, enalapril, and spironolactone or indomethacin, enalapril, and spironolactone plus acetazolamide once daily in the morning for 4 weeks. After 2 days of washout, participants crossed over to receive the alternative intervention for 4 weeks. The present study examines the serum bicarbonate lowering effect of acetazolamide as an adjunctive therapy in children with Batter syndrome. RESULTS: Of the 43 patients screened for eligibility, 22 (51%), between the ages 6 and 42 months, were randomized to intervention. Baseline characteristics were similar between the two groups. Addition of acetazolamide for a period of 4 weeks significantly reduced serum bicarbonate and increased serum potassium levels, parallel with a reduction in serum aldosterone and plasma renin concentration. The 24-h urine volume, sodium, potassium, and chloride decreased significantly. CONCLUSION: Our data define a new physiologic and therapeutic role of acetazolamide for the management of children with Bartter syndrome.
Authors: D B Simon; F E Karet; J Rodriguez-Soriano; J H Hamdan; A DiPietro; H Trachtman; S A Sanjad; R P Lifton Journal: Nat Genet Date: 1996-10 Impact factor: 38.330
Authors: William B White; Christine R West; Jeffrey S Borer; Philip B Gorelick; Lisa Lavange; Sharon X Pan; Ethan Weiner; Kenneth M Verburg Journal: Am J Cardiol Date: 2006-11-10 Impact factor: 2.778
Authors: Kamel Laghmani; Bodo B Beck; Sung-Sen Yang; Elie Seaayfan; Andrea Wenzel; Björn Reusch; Helga Vitzthum; Dario Priem; Sylvie Demaretz; Klasien Bergmann; Leonie K Duin; Heike Göbel; Christoph Mache; Holger Thiele; Malte P Bartram; Carlos Dombret; Janine Altmüller; Peter Nürnberg; Thomas Benzing; Elena Levtchenko; Hannsjörg W Seyberth; Günter Klaus; Gökhan Yigit; Shih-Hua Lin; Albert Timmer; Tom J de Koning; Sicco A Scherjon; Karl P Schlingmann; Mathieu J M Bertrand; Markus M Rinschen; Olivier de Backer; Martin Konrad; Martin Kömhoff Journal: N Engl J Med Date: 2016-04-27 Impact factor: 91.245
Authors: Stephan C Reinalter; Nikola Jeck; Christoph Brochhausen; Bernhard Watzer; Rolf M Nüsing; Hannsjörg W Seyberth; Martin Kömhoff Journal: Kidney Int Date: 2002-07 Impact factor: 10.612